Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have been assigned a consensus recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $199.5333.

A number of analysts have weighed in on PVLA shares. Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. TD Cowen reiterated a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. BTIG Research increased their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Mizuho increased their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Truist Financial set a $210.00 target price on Palvella Therapeutics in a research note on Tuesday, February 24th.

Insiders Place Their Bets

In other news, Director George M. Jenkins purchased 4,000 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were purchased at an average price of $125.00 per share, for a total transaction of $500,000.00. Following the completion of the purchase, the director owned 187,171 shares in the company, valued at approximately $23,396,375. This represents a 2.18% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Elaine J. Heron purchased 2,400 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were purchased at an average price of $125.00 per share, for a total transaction of $300,000.00. Following the purchase, the director owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. This trade represents a 5.28% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Several institutional investors have recently made changes to their positions in the company. Federated Hermes Inc. purchased a new position in Palvella Therapeutics during the third quarter valued at approximately $21,255,000. Aberdeen Group plc purchased a new position in Palvella Therapeutics in the third quarter valued at about $3,212,000. First Light Asset Management LLC purchased a new position in Palvella Therapeutics in the third quarter valued at about $33,949,000. Apis Capital Advisors LLC purchased a new position in Palvella Therapeutics in the third quarter valued at about $627,000. Finally, Suvretta Capital Management LLC grew its stake in Palvella Therapeutics by 15.1% in the third quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock valued at $51,556,000 after purchasing an additional 107,937 shares during the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $113.99 on Friday. The stock’s fifty day moving average is $121.93 and its 200 day moving average is $105.45. Palvella Therapeutics has a fifty-two week low of $20.20 and a fifty-two week high of $151.18. The firm has a market capitalization of $1.63 billion, a PE ratio of -27.34 and a beta of -0.13.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). Equities analysts forecast that Palvella Therapeutics will post -5.43 EPS for the current year.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.